Abstract
Dual antiplatelet therapy with aspirin and clopidogrel is the standard of care for patients with acute coronary syndrome(ACS) and those who undergoing percutaneous coronary intervention(PCI).However,clopidogrel has drawbacks which leads to find the ideal antiplatelet therapy.The higher-than-standard clopidogrel dosing regimens provided greater inhibition of platelet function and improved clinical outcomes with a small but significant increase in major bleeding.Newer,more potent antiplatelet agents such as prasugrel and ticagrelor results in the best short-and long-term outcomes for patients with ACS or those undergoing PCI.The related research advances are reviewed in this paper.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
